Clinical Trials
5 trialsNCT07523529 2026-04-13
SELECT-2CAR
Beijing Biotech
Phase 1/2 Recruiting
NCT07486089 2026-03-20
DUAL-NK-BC
Beijing Biotech
Phase 1/2 Recruiting
NCT05451849 2025-08-27
A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
TCR2 Therapeutics
Phase 1/2 Active not recruiting
NCT06532812 2024-11-12
BAH249
Essen Biotech
Phase 1/2 Recruiting
NCT04639245 2023-08-03
Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer
Fred Hutchinson Cancer Center
Phase 1/2 Terminated